At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 30 enrolled
Drug / intervention
sodium fusidatedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-Label, Non-Randomized, Single-Arm, Multi-Center Study to Evaluate Oral Sodium Fusidate (CEM-102) for the Treatment of Staphylococcal Bone or Joint Infections in Subjects for Whom Chronic Antibiotic Suppressive Therapy is Indicated
In Brief
A Phase 3 clinical trial evaluating sodium fusidate for Refractory Bone or Joint Infections. Completed, enrolled 30 participants across 19 sites.
Detailed Summary
To evaluate the safety and effectiveness of oral sodium fusidate (CEM-102) as chronic antibiotic for the treatment of bone or joint infections.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRefractory Bone or Joint Infections
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
20162017201820192020202120222023202420252026
First PostedOct 2015
Enrollment StartDec 2015
Primary CompletionOct 2017
Study CompletionFeb 2019
TodayJul 2026
First PostedOct 6, 2015
Enrollment StartDec 1, 2015
Primary CompletionOct 17, 2017
Study CompletionFeb 21, 2019
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 10.7 years ago
Interventions
sodium fusidatedrug